Model Organisms in Drug Discovery

REFERENCES 179
Austin, J. and Kimble, J. (1989). Transcript analysis of glp-1 and lin-12, homologous genes
required for cell interactions during development of C. elegans. Cell 58, 565–571.
Basson, M. E., Thorsness, M. and Rine, J. (1986). Saccharomyces cerevisiae contains two
functional genes encoding 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Proc.
Natl. Acad. Sci. USA 83, 5563–5567.
Beitel, G. J., Clark, S. G. and Horvitz, H. R. (1990). Caenorhabditis elegans ras gene let-60
acts as a switch in the pathway of vulval induction. Nature 348, 503–509.
Brune, K. (2002). Next generation of everyday analgesics. Am. J. Ther. 9, 215–223.
Bynum, W. F. (1970). Chemical structure and pharmacological action: a chapter in the
history of 19th century molecular pharmacology. Bull. Hist. Med. 44, 518–538.
Capdeville, R., Buchdunger, E., Zimmermann, J. and Matter, A. (2002). Glivec (STI571,
imatinib), a rationally developed, targeted anticancer drug. Nat. Rev. Drug Discov. 1,
493–502.
Caplen, N. J., Fleenor, J., Fire, A. and Morgan, R. A. (2000). dsRNA-mediated gene
silencing in cultured Drosophila cells: a tissue culture model for the analysis of RNA
interference. Gene 252, 95–105.
Caplen, N. J., Parrish, S., Imani, F., Fire, A. and Morgan, R. A. (2001). Specific inhibition
of gene expression by small double-stranded RNAs in invertebrate and vertebrate
systems. Proc. Natl. Acad. Sci. USA 98, 9742–9747.
Caponigro, F. (2002). Farnesyl transferase inhibitors: a major breakthrough in anticancer
therapy? Naples, 12 April 2002. Anticancer Drugs 13, 891–897.
Chandrasekharan, N. V., Dai, H., Roos, K. L., Evanson, N. K., Tomsik, J., Elton, T. S.
and Simmons, D. L. (2002). From the Cover: COX-3, a cyclooxygenase-1 variant
inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure,
and expression. Proc. Natl. Acad. Sci. USA 99, 13 926–13 931.
Choe, K. M., Werner, T., Stoven, S., Hultmark, D. and Anderson, K. V. (2002).
Requirement for a peptidoglycan recognition protein (PGRP) in Relish activation and
antibacterial immune responses in Drosophila. Science 296, 359–362.
Choy, R. K. and Thomas, J. H. (1999). Fluoxetine-resistant mutants in C. elegans define a
novel family of transmembrane proteins. Mol. Cell 4, 143–152.
Clemens, J. C., Worby, C. A., Simonson-Leff, N., Muda, M., Maehama, T., Hemmings,
B. A. and Dixon, J. E. (2000). Use of double-stranded RNA interference in Drosophila
cell lines to dissect signal transduction pathways. Proc. Natl. Acad. Sci. USA 97, 6499–
6503.
Culetto, E. and Sattelle, D. B. (2000). A role for Caenorhabditis elegans in understanding
the function and interactions of human disease genes. Hum. Mol. Genet. 9, 869–877.
Cully, D. F., Vassilatis, D. K., Liu, K. K., Paress, P. S., Van der Ploeg, L. H., Schaeffer,
J. M. and Arena, J. P. (1994). Cloning of an avermectin-sensitive glutamate-gated
chloride channel from Caenorhabditis elegans. Nature 371, 707–711.
Drews, J. and Ryser, S. (1997). The role of innovation in drug development. Nat.
Biotechnol. 15, 1318–1319.
Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K. and Tuschl, T. (2001).
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian
cells. Nature 411, 494–498.
Esler, W. P. and Wolfe, M. S. (2001). A portrait of Alzheimer secretases – new features and
familiar faces. Science 293, 1449–1454.
Esler, W. P., Kimberly, W. T., Ostaszewski, B. L., Diehl, T. S., Moore, C. L., Tsai, J. Y.,
Rahmati, T., et al. (2000). Transition-state analogue inhibitors of gamma-secretase bind
directly to presenilin-1. Nat. Cell Biol. 2, 428–434.